NEW YORK (GenomeWeb News) – Pacific Biosciences today said that it has acquired Li-Cor Biosciences’ single molecule sequencing technology, called sequencing by incorporation.
The acquisition complements Pacific Bio’s current sequencing technology — SMRT, or single molecule real-time, sequencing method.
Li-Cor’s technology identifies nucleotides in a DNA sequence based upon synthesis of a complementary DNA strand. Pacific Bio acquired a number of issued US and foreign patents covering the technology, as well as pending US applications.
Menlo Park, Calif.-based Pacific Bio said that Li-Cor has retained rights to intellectual property for sequencing enzymes that were designed for sequencing by polymerase synthesis. It noted that Li-Cor has an active out-licensing program for those enzymes.
In addition to the acquisition, Pacific Bio said that the agreement includes ongoing opportunities to collaborate with Li-Cor’s scientists on sequencing enzymes.
"Li-Cor's early developments in the field of sequencing by incorporation, as well as their comprehensive intellectual property portfolio surrounding those developments, provide a unique and attractive opportunity for us to combine our resources to build a strong foundation from which to ultimately deliver on the huge advantages of single molecule real time sequencing by synthesis," Hugh Martin, Pacific Biosciences chairman and CEO, said in a statement.